DexCom, Inc. - Common Stock (DXCM)

DexCom, Inc. (NASDAQDXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold a conference call to review the company's fourth quarter and fiscal year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.

DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the fourth quarter of 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4% over the fourth quarter of 2023. International revenue is expected to be approximately $310 million, an increase of 17% over the fourth quarter of 2023.

DexCom, Inc. (NASDAQDXCM) today announced that management will present an update on the company at the 43rd annual J.P. Morgan Healthcare Conference on January 13, 2025.

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into DexCom, Inc. (“DexCom” or the “Company”) (NasdaqGS: DXCM).

DexCom, Inc. (NASDAQDXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health.

DexCom, Inc. (NASDAQDXCM), the global leader in glucose biosensing, and ŌURA, maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. Combining Dexcom glucose data with the biometrics collected by Oura Ring will provide users of both products with a more complete picture of overall health. Dexcom is also making a $75 million strategic investment in ŌURA Series D funding, with ŌURA now valued at more than $5 billion.

This World Diabetes Day, DexCom, Inc. (NASDAQDXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first step to discover what they’re made of. This comes as global data1 shows nearly 70% of people with diabetes say they didn’t know where to begin their health journey when they were first diagnosed, and nearly half said diabetes has limited their ability to pursue a passion or interest.

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024.

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQDXCM) on behalf of long-term stockholders following a class action complaint that was filed against DexCom on August 21, 2024 with a Class Period from April 28, 2023 to July 25, 2024. Our investigation concerns whether the board of directors of DexCom have breached their fiduciary duties to the company.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQDXCM) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQDXCM) between January 8, 2024 and July 25, 2024. DexCom describes itself as an “international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management.”

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQDXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”).

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Orthofix Medical Inc. (NASDAQOFIX), Spire Global, Inc. NYSE:SPIRNYSESPIR)(NASDAQ: DXCMNASDAQDXCM, and Methode Electronics Inc. (NYSE: MEINYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (“DexCom”) (NASDAQDXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024.

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) --

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Orthofix Medical Inc. (NASDAQOFIX), Spire Global, Inc. NYSE:SPIRNYSESPIR)(NASDAQ: DXCMNASDAQDXCM, and Methode Electronics Inc. (NYSE: MEINYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Labaton Keller Sucharow LLP (“Labaton”) announces that, on October 8, 2024, it filed a securities class action lawsuit (the “Complaint”) on behalf of its clients Oakland County Employees’ Retirement System and Oakland County Voluntary Employees’ Beneficiary Association (the “Oakland County Funds”) against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQDXCM) and certain DexCom officers (collectively, “Defendants”). The action, which is captioned Oakland County Employees’ Retirement System v. DexCom, Inc., No. 24-cv-01804-AJB-BLM (S.D. Cal. Oct. 8, 2024) asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder, on behalf of all persons or entities who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”).

NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Orthofix Medical Inc. (NASDAQOFIX), Spire Global, Inc. NYSE:SPIRNYSESPIR)(NASDAQ: DXCMNASDAQDXCM, and Methode Electronics Inc. (NYSE: MEINYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options